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OBJECTIVE—The aim of this study was to ﬁnd an effective
treatment for the genetic form of diabetes that is present in some
Huntington’s disease patients and in Huntington’s disease mouse
models. Huntington’s disease is a neurodegenerative disorder
caused by a polyglutamine expansion within the huntingtin
protein. Huntington’s disease patients exhibit neuronal dysfunc-
tion/degeneration, chorea, and progressive weight loss. Addition-
ally, they suffer from abnormalities in energy metabolism
affecting both the brain and periphery. Similarly to Huntington’s
disease patients, mice expressing the mutated human huntingtin
protein also exhibit neurodegenerative changes, motor dysfunc-
tion, perturbed energy metabolism, and elevated blood glucose
levels.
RESEARCH DESIGN AND METHODS—Huntington’s disease
mice were treated with an FDA-approved antidiabetic glucagon-
like peptide 1 receptor agonist, exendin-4 (Ex-4), to test whether
euglycemia could be achieved, whether pancreatic dysfunction
could be alleviated, and whether the mice showed any neurolog-
ical beneﬁt. Blood glucose and insulin levels and various appetite
hormone concentrations were measured during the study. Addi-
tionally, motor performance and life span were quantiﬁed and
mutant huntingtin (mhtt) aggregates were measured in both the
pancreas and brain.
RESULTS—Ex-4 treatment ameliorated abnormalities in periph-
eral glucose regulation and suppressed cellular pathology in both
brain and pancreas in a mouse model of Huntington’s disease.
The treatment also improved motor function and extended the
survival time of the Huntington’s disease mice. These clinical
improvements were correlated with reduced accumulation of
mhtt protein aggregates in both islet and brain cells.
CONCLUSIONS—Targeting both peripheral and neuronal deﬁ-
cits, Ex-4 is an attractive agent for therapeutic intervention in
Huntington’s disease patients suffering from diabetes. Diabetes
58:318–328, 2009
H
untington’s disease is an inherited neurodegen-
erative disorder typiﬁed by involuntary body
movements and psychiatric and cognitive ab-
normalities. The incidence of Huntington’s dis-
ease is 5–10 cases per 100,000 worldwide, making it one
of the most common inherited neurodegenerative disor-
ders (1). The genetic defect underlying Huntington’s dis-
ease involves expansion of CAG trinucleotide repeats in
exon 1 of the Huntington’s disease gene, resulting in
polyglutamine expansions in the huntingtin (htt) protein
(2). Polyglutamine expansion in htt leads to its abnormal
processing and deleterious intracellular aggregation. The
number of polyglutamine repeats in htt is inversely corre-
lated with the age of onset, with 70–100 repeats leading to
juvenile onset (1). The wild-type htt protein is thought to
be a scaffolding protein involved in multiple processes,
including vesicle movement and cell metabolism. Mutant
htt forms abnormal intracellular aggregates in degenerat-
ing neurons in the striatum and cerebral cortex (3).
Despite being considered primarily a neurological dis-
order, Huntington’s disease patients also exhibit periph-
eral symptoms, including progressive weight loss, appetite
dysfunction, and poor glycemic control (4). Huntington’s
disease patients suffer from an unusual combination of a
hypermetabolic state due in part to continuous body
movements (5), and despite this, glucose metabolism is
paradoxically impaired in both brain and periphery (6,7).
Dietary supplementation with creatine has been shown to
reduce brain damage and delay the onset of motor dys-
function in huntingtin mutant mice (8), which suggests a
potential beneﬁt of increasing brain energy availability in
Huntington’s disease. High levels of mutant htt have been
documented in peripheral tissues, including muscle and
gonads (9), and in the pancreatic islet cells of the R6/2
Huntington’s disease mice, which exhibit decreased -cell
mass and impaired insulin release capacity (10,11). How-
ever, the “diabetic-like” condition in the Huntington’s
disease mice is not improved by treatment with hypogly-
cemic agents, such as insulin or metformin (12,13). Dis-
ruption of glycemic homeostasis is likely to affect nutrient
availability to neurons and could alter neuronal function
and contribute to neurodegeneration and motor deﬁcits in
Huntington’s disease. The emerging view of Huntington’s
disease as a “body-wide” disorder supports the increasing
evidence that the maintenance of a healthy nervous sys-
tem is tightly linked with peripheral metabolic health (14).
Therefore, treatment of both the peripheral and central
pathophysiologies of Huntington’s disease could form the
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strategy.
Glucagon-like peptide-1 (GLP-1), a hormone secreted by
intestinal enteroendocrine L-cells in response to food
ingestion and the natural ligand of the GLP-1 receptor, acts
on multiple target tissues to enhance energy metabolism;
it stimulates the production and release of insulin from
-cells in islets of Langerhans in the pancreas and in-
creases insulin sensitivity by multiple mechanisms (15,16).
These actions, however, appear to be highly complicated
and context speciﬁc because several studies have not
demonstrated a link between GLP-1 activity and increases
in insulin sensitivity (17). The antidiabetic actions of
GLP-1 have been shown to improve glucose regulation in
human subjects (18), and a long-acting GLP-1 receptor
agonist, exendin-4 (Ex-4), is now a treatment for type 2
diabetes (19). In addition to peripheral actions, GLP-1 and
Ex-4 have been shown to act on neurons in the brain.
GLP-1 receptors are widely expressed in neurons through-
out the brain (20), and Ex-4 readily crosses the blood-brain
barrier (21). GLP-1 and Ex-4 have been shown to exert
neuroprotective actions in experimental models of excito-
toxic brain injury (22) and peripheral neuropathy (23). The
antidiabetic and direct neuroprotective activities of Ex-4
suggested to us its potential to ameliorate both the central
and peripheral abnormalities in Huntington’s disease. We
therefore determined whether daily administration of Ex-4
could attenuate disease progression and alleviate meta-
bolic abnormalities in the N171-82Q mouse model of
Huntington’s disease. Our ﬁndings show that Ex-4 treat-
ment suppresses the development of mutant huntingtin
(mhtt) inclusions in the pancreas and brain, ameliorates
metabolic defects and motor dysfunction, and extends the
survival of Huntington’s disease mice.
RESEARCH DESIGN AND METHODS
Animals and drug administration. Forty male B6C3-Tg(HD82Gln)81Dbo/J
(common name N171-82Q) mice (24) and 43 age-matched wild-type mice were
used in this study. Transgenic mice were identiﬁed by PCR analysis of tail
DNA. All procedures using these Huntington’s disease mice and their wild-
type littermates were approved by the institutional Animal Care and Use
Committee of the National Institute on Aging. The N171-82Q mice express 82
CAG repeats and display many Huntington’s disease–like symptoms, including
huntingtin aggregate formation in and degeneration of striatal and cortical
neurons, motor impairment, progressive weight loss, and signiﬁcantly ele-
vated plasma glucose levels (24). All mice were group housed on a 12-h
light/12 h dark cycle and had ad libitum access to food and water. Either Ex-4
(Bachem, Torrance, CA) or saline (PBS; Sigma, St. Louis, MO) was adminis-
tered by a once-daily subcutaneous injection (300 l 0.1-mol/l solution of
Ex-4). This study was repeated in multiple cohorts of the N171-82Q mice.
Body weight and glucose measurements. Body weight (g) and blood
glucose levels (mg/dl) were measured weekly. Glucose levels were measured
in blood collected from the tail vein blood using a Bayer Glucometer Elite XL
blood glucose meter.
In vivo insulin sensitivity test. An insulin tolerance test was performed on
a cohort of mice (six to eight animals per group) to investigate insulin
sensitivity. Human, rapid-acting insulin (Novo Nordisk) was diluted to 0.1
unit/ml in isotonic NaCl 0.05% BSA (Sigma). The mice were injected subcu-
taneously in the neck region with 1 mU/g body wt insulin, and blood glucose
levels were measured at various time points (t  0, 15, 30, 45, 60, 90, and 120
min) from the tail vein using a Bayer Glucometer Elite XL blood glucose
meter.
Motor performance assessment. Motor coordination was tested using an
accelerating rotarod (Med. Associates, Georgia, VT). Mice were trained to use
the rotarod apparatus during a 2-min habituation trial (4 rpm) on the day
before the ﬁrst day of testing. On test days the rotarod apparatus was
gradually accelerated from 4 to 40 rpm over 5 min. The latency to fall was
measured and averaged over two trials per test day. Testing was started the
week before initial treatment and continued bi-weekly throughout the course
of the study.
Tissue collection. Mice were killed by isoﬂuorene overdose inhalation and
decapitation. Brains were removed, and the cerebral cortex was isolated by
dissection. Additionally, the pancreas was removed from each animal, and
blood was collected for analyses of energy metabolism hormones. Blood was
centrifuged at 3,000 rpm for 30 min at 4°C, and plasma was aspirated off. The
pancreata were ﬁxed in 4% formalin for 48 h and stored in PBS until
processing. The pancreatic tissue was processed and embedded in parafﬁn
wax. Pancreatic sections were cut at 5 m thickness using a microtome, and
the sections were adhered to poly-L-lysine coated microscope slides (Fisher,
Springﬁeld, NJ).
Insulin and glucagon immunohistochemistry. Pancreatic sections were
immunostained according to a previously described protocol (25). Brieﬂy,
tissue was incubated with the primary insulin antibody (guinea pig anti-swine
insulin; 1:300; DakoCytomation, Carpinteria, CA) or glucagon antibody (1:500;
guinea pig anti-glucagon; Millipore, Billerica, MA) for2ha troom temperature
and then incubated with secondary antibody (Alexa Fluor 488 goat anti–
guinea pig, 1:200; or Alexa Fluor 568 goat anti–guinea pig, 1:1,000; Invitrogen,
Carlsbad, CA) for1ha troom temperature. Sections were imaged with an
Olympus Fluoview IX70 confocal microscope (Olympus America, Center
Valley, PA).
Pancreatic islet image analysis. Quantiﬁcation of immunohistochemistry
images was performed in Matlab (Mathworks) using novel software in
conjunction with the image processing toolbox. Intensity readings of each
image ranged from 0 to 256, with 256 being the greatest pixel density and
hence the highest staining intensity. The region of interest (ROI) was drawn
around each islet after background subtraction. The pixels within the bounds
of the ROI and above the set threshold of 8 were selected, from which actual
islet area was calculated. The normalized variance of the ROI was used to
calculate an artiﬁcial ellipse from which the major and minor axes were
determined. The major axis is the longest diameter that can be drawn in the
ellipse, and the minor axis is the shortest diameter, both giving an accurate
approximation for the range of the actual islet diameter. Islet morphometry
and sizing analyses were performed in an unbiased, random fashion.
Adipokine and hormone measurements. These were measured by ELISA
and radioimmunoassay (RIA) methods according to the kit manufacturers’
instructions: adiponectin (ELISA; Linco Research, St. Charles, MO), leptin
(ELISA; Crystal Chem, Downers Grove, IL), insulin (ELISA; Crystal Chem),
and ghrelin (RIA; Phoenix Pharmaceuticals, Belmont, CA). Homeostatic
model of insulin resistance values (HOMA) were calculated from glucose and
insulin values using the HOMA2 software available from the Oxford Centre for
Diabetes, Endocrinology, and Metabolism Diabetes Trials Unit (www.dtu.ox.
ac.uk).
Western immunoblotting. Cortex samples were homogenized and sonicated
in a Nonidet P-40–based lysis buffer, as described previously (26). Subse-
quently, the samples were centrifuged at 14,000 rpm for 15 min, and the
supernatant was removed for protein analysis. Samples were diluted 1:1 with
Laemmli buffer and resolved by SDS-PAGE. Proteins were then transferred
onto a polyvinylidine ﬂuoride membrane for immunoblotting. Membranes
were blocked by soaking in methanol, allowed to air dry, and then incubated
with primary antibody diluted in a 4% BSA, 50 mmol/l Tris-HCl, pH 7.0, 0.05%
Tween 20, and 0.05% Nonidet P-40 blocking solution for1ha troom
temperature (S830 anti-HD exon 1 transgene protein, goat polyclonal, 1:3,000;
anti–heat shock protein-70 [anti–Hsp-70] mouse monoclonal [Stressgen, Ann
Arbor, MI], 1:1,000; anti-actin, mouse monoclonal [Sigma], 1:3,000). Mem-
branes were probed with secondary alkaline phosphatase antibody diluted in
4% BSA/TBS-T solution for 1 h (anti-goat or anti-mouse IgG; 1:3,000; Sigma)
and then developed with ECF Substrate (GE Healthcare). A Typhoon 9410
Variable Mode Imager (Amersham Biosciences) was used for signal detection,
and band intensities were calculated using ImageQuant software (Molecular
Dynamics).
mhtt immunohistochemistry. Pancreatic sections were immunostained as
previously described (27). S830, a goat polyclonal antibody to the Hunting-
ton’s disease exon 1 transgene protein, was used at a dilution of 1:2,000. A
biotinylated secondary rabbit anti-goat antibody was used at 1:500 (Vector
Laboratories, Burlingame, CA). Slices were complexed with avidin-biotin
using a Vectastain Elite ABC kit (Vector Laboratories) and developed using a
Dako Liquid DAB Substrate Chromogen System (DakoCytomation). Images
were acquired using an Olympus Fluoview IX70 confocal microscope and
Nikon Coolpix P5000 digital camera.
Statistical analyses. The data represent the means  SE. Differences
between mean values for variables within individual experiments were
compared statistically by Student’s t test and ANOVA. Comparisons were
performed by using Graphpad Prism (GraphPad Software, San Diego, CA) and
Excel. P  0.05 was considered statistically signiﬁcant.
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Ex-4 treatment induces euglycemia in Huntington’s
disease mice. Presymptomatic male N171-82Q Hunting-
ton’s disease mice (which express cDNA encoding an
NH2-terminal fragment [171 amino acids] of huntingtin
with 82 glutamines) and age-matched male wild-type lit-
termates were injected daily with either Ex-4 or saline
(control). Body weight and nonfasting plasma glucose
levels were measured weekly, and motor coordination was
measured bi-weekly (Fig. 1A). Daily Ex-4 treatment in the
wild-type mice resulted in a small reduction in resting
glucose levels, compared with the saline-treated control
wild-type mice (Fig. 2A). The Huntington’s disease mice
exhibited signiﬁcantly elevated plasma glucose levels com-
pared with the wild-type mice (Fig. 2B), which corrobo-
rates with previous reports of elevated peripheral blood
glucose levels in Huntington’s disease mouse models
(10,13). Daily treatment with Ex-4 resulted in a signiﬁcant
and progressive reduction in glucose levels in the Hunting-
ton’s disease mice (P  0.05; Fig. 2B). Mean blood glucose
levels across the whole study period were signiﬁcantly
reduced in the wild-type Ex-4–treated mice (P  0.05; Fig.
2C) and to a much greater extent in the Ex-4–treated
Huntington’s disease mice (P  0.001; Fig. 2D). We at-
tempted to achieve euglycemia in the Huntington’s disease
mice by administering daily or twice-daily injections of
long-acting insulin (Glargine); however, we were unable to
affect plasma glucose levels in the Huntington’s disease
mice, even with a high dose of insulin (up to 8 IU/kg), and
animals died more quickly than nontreated Huntington’s
disease mice (data not shown). The insensitivity of the
N171-82Q mice to insulin is similar to that reported for
R6/2 mice, another Huntington’s disease mouse model,
treated with insulin or metformin (12,13).
Severe and progressive weight loss is a common symp-
tom of Huntington’s disease that also occurs in many
mouse models of Huntington’s disease (8,10). The control
Huntington’s disease mice lost a signiﬁcant amount of
Pre-symptomatic Daily Exendin-4 injections
Rotarod
Weight/Glucose
N171-82Q
Euthanize:
pancreas, brain & 
plasma collected
Rotarod Rotarod Rotarod Rotarod
Weight/Glucose Weight/Glucose Weight/Glucose Weight/Glucose
A
GLP-1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR
EXENDIN-4 HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS
B
C
Control HD
Gut
Stomach
Pancreas
Brain
Gut
Stomach
Pancreas
Exendin-4 HD
Brain
Insulin 
sensitivity
GLP-1
Plasma 
glucose
GLP-1
Plasma 
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Insulin 
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FIG. 1. Experimental design. A: Experimental timeline of the study. Male N171-82Q and age-matched wild-type mice were injected daily with
either Ex-4 or saline (control). Body weight and glucose measurements were recorded weekly, and rotarod performance was assessed bi-weekly.
On euthanization, cortex, pancreas, and plasma were collected for further analyses. B: Ex-4 is an agonist of the GLP-1 receptor. Several amino
acids differ between GLP-1 and Ex-4 sequences, most importantly in the NH2-terminal region where the substitution of alanine to glycine renders
Ex-4 resistant to proteolysis by dipeptidyl peptidase-IV. Whereas GLP-1 has a half-life of <2 min in circulation, Ex-4 has biological activity for
6 h. This ensures that Ex-4 has potent and long-acting effects on both the periphery (pancreas) and the brain. C: Proposed mechanisms of action
of Ex-4 in peripheral tissues and the brain. Ex-4 promotes pancreatic -cell growth and insulin production and secretion and increases insulin
sensitivity of muscle and liver cells. Ex-4 crosses the blood-brain barrier and acts on neurons in the brain to promote their survival and support
their high energy demands.
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their weight was signiﬁcantly lower than the control wild-
type mice (P  0.001). Ex-4 treatment exacerbated this
weight loss, and both the Huntington’s disease and wild-type
Ex-4–treated mice weighed signiﬁcantly less than their sa-
line-treated control counterparts (P  0.001, P  0.01; Fig.
2E–H). This reduction in body weight is in accord with
previous reports that have shown that Ex-4 treatment leads
to progressive weight loss in human subjects (28).
Energy- and appetite-regulating hormones are al-
tered by Ex-4 treatment. An alteration in energy ho-
meostasis has been reported in Huntington’s disease
patients and in several of the Huntington’s disease mouse
models (29,30). A disruption in energy balance could
contribute to some of the Huntington’s disease symptom-
ology, including extreme weight loss and alterations in
appetite. We measured plasma levels of the main energy-
regulating hormones in the Huntington’s disease and wild-
type mice to determine whether Ex-4 had caused any
alterations in these hormones. Ex-4 treatment induced a
signiﬁcant reduction in plasma insulin levels in the wild-
type mice (P  0.05) and a small reduction in plasma
insulin levels in the Huntington’s disease mice (Fig. 3A and
B). Ex-4 is a proven and effective treatment for type 2
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FIG. 2. Ex-4 normalizes plasma glucose levels in Huntington’s disease mice (right panel). Weekly (A and B) and average (C and D) glucose levels
of saline- and Ex-4–treated wild-type (left panel) and Huntington’s disease mice are shown throughout the treatment period. Ex-4 treatment
signiﬁcantly reduced plasma glucose levels in Huntington’s disease mice from the ﬁrst week of treatment, and euglycemia was maintained
throughout the course of the study period. Ex-4 also signiﬁcantly reduced plasma glucose levels in wild-type mice. Weekly (E and F) and average
(G and H) body weight measurements for saline- and Ex-4–treated wild-type and Huntington’s disease mice throughout the study are shown. Ex-4
treatment caused a signiﬁcant reduction in body weight in both wild-type and Huntington’s disease mice. Values are means  SE, n  18–24
animals per group. *P < 0.05, **P < 0.01, ***P < 0.001.
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DIABETES, VOL. 58, FEBRUARY 2009 321diabetes, because it not only protects pancreatic -cell
function, but it also signiﬁcantly increases insulin sensitiv-
ity (31,32). Ex-4 treatment increased insulin sensitivity by
50% in the Huntington’s disease mice (Fig. 3B, inset), as
judged by the HOMA. Because the HOMA index was
created to measure classic diabetic states and not the
idiosyncratic diabetic pathophysiology in Huntington’s dis-
ease mice, we also used an insulin tolerance test in a
separate cohort of animals to assess insulin resistance.
This demonstrated that Ex-4 improved insulin-stimulated
glucose uptake in both Huntington’s disease and wild-type
animals (supplementary Fig. 1, available in an online
appendix at http://dx.doi.org/10.2337/db08-0799).
The extreme and uncontrolled weight loss in Huntington’s
disease patients and mice has been linked to alterations in
hypothalamic function (29), including perturbations of the
gastric hormone ghrelin and the adipocyte hormone leptin
(30). Compared with wild-type animals, the Huntington’s
disease mice had signiﬁcantly lower leptin, ghrelin, and
adiponectin levels (Fig. 3C–H). In both wild type and
Huntington’s disease mice, Ex-4 treatment signiﬁcantly
lowered plasma leptin levels (Fig. 3C and D; wild type, P 
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FIG. 3. Modiﬁcation of plasma levels of energy-regulating hormones by Ex-4 treatment in wild-type (left panel) and Huntington’s disease (right
panel) mice. Plasma concentrations of insulin (A and B), leptin (C and D), ghrelin (E and F), and adiponectin (G and H) were measured in
wild-type and Huntington’s disease mice treated with either saline (control) or Ex-4. Ex-4 treatment signiﬁcantly reduced plasma insulin levels
in wild-type mice, compared with control wild-type animals (P < 0.05). In Huntington’s disease mice, Ex-4 treatment did not signiﬁcantly alter
circulating levels of insulin compared with Huntington’s disease control animals. Thus, despite having lower circulating levels of insulin, the
Ex-4–treated wild-type and Huntington’s disease mice exhibit improved insulin sensitivity, as demonstrated by the reduction in plasma glucose
levels (A and B). B, inset: Using plasma insulin and glucose measurements, HOMA values were calculated. C and D: Ex-4 treatment signiﬁcantly
reduced leptin levels in both wild-type (P < 0.001) and Huntington’s disease (P < 0.05) mice, consistent with the decrease in the body weight in
the Ex-4–treated mice. E and F: There were no signiﬁcant effects of Ex-4 on plasma ghrelin levels in wild-type and Huntington’s disease mice,
although there were trends toward decreased levels in the wild-type mice and increased levels in the Huntington’s disease mice. G and H: There
were no signiﬁcant alterations in the plasma adiponectin levels with Ex-4 treatment for both the wild-type and Huntington’s disease mice, and
Huntington’s disease mice had signiﬁcantly lower plasma adiponectin levels compared with wild-type mice (P < 0.01). Values are means  SE,
n  18–24 animals per group. *P < 0.05, ***P < 0.001.
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levels were reduced in the Ex-4–treated wild-type mice
compared with the control wild-type mice (Fig. 3E), and
this effect has also been observed in human subjects (33).
The control Huntington’s disease mice had signiﬁcantly
lower ghrelin levels compared with the wild-type mice,
and Ex-4 treatment unexpectedly restored ghrelin levels in
the Huntington’s disease mice to that of wild-type mice
(Fig. 3F). This suggests that Ex-4 treatment might amelio-
rate some of the appetite-related dysfunctions in Hunting-
ton’s disease patients. Ex-4 treatment did not affect plasma
adiponectin levels in Huntington’s disease or wild-type
mice (Fig. 3G and H), although adiponectin levels were
signiﬁcantly lower in the Huntington’s disease mice com-
pared with the wild-type mice (P  0.001). Decreased
adiponectin levels are a universal ﬁnding in insulin-resis-
tant states (34).
Ex-4 improves pancreatic islet structure in Hunting-
ton’s disease mice. In the N171-82Q mice and in other
Huntington’s disease mouse models, there is a build-up of
mhtt aggregates within the islets of Langerhans, which
may contribute to their “diabetic-like” condition (11).
Huntington’s disease mice showed signiﬁcant alterations
in islet structure, evidenced by greatly reduced numbers of
insulin immunoreactive -cells compared with their wild-
type control counterparts (Fig. 4A and B). Ex-4 treatment
restored numbers of -cells in the Huntington’s disease
mice to levels close to those of wild-type mice (Fig. 4C and
D; Table 1). The alterations in islet size and structure were
also conﬁrmed by glucagon staining. In control and Ex-4–
treated wild-type mice, the glucagon-expressing -cells
were situated on the periphery of the islets (Fig. 4E and
G). In Huntington’s disease mice, some of the -cells were
displaced into the center of the islets (Fig. 4F), causing
abnormal islet structure. Ex-4 treatment largely restored
the -cell topography of islets in the Huntington’s disease
mice (Fig. 4H).
Motor coordination is improved in Ex-4–treated
Huntington’s disease mice. Motor coordination was
measured on a bi-weekly basis using an accelerating
rotarod (Fig. 5A and B). As Huntington’s disease patients
and Huntington’s disease mice become symptomatic, they
exhibit impaired motor coordination (8,35). The Hunting-
ton’s disease control mice spent signiﬁcantly less time on
the rotarod than the wild-type control mice, which indi-
cates that motor function was signiﬁcantly impaired in the
Huntington’s disease control mice. Ex-4 treatment signiﬁ-
cantly enhanced the ability to stay on the rotarod for both
wild-type (P  0.05) and Huntington’s disease (P  0.05)
mice. Generally, the wild-type and Huntington’s disease
mice that were treated with Ex-4 showed increased levels
of general activity in their home cages (data not shown).
We propose that the improved performance of the wild-
type Ex-4–treated mice on the rotarod could be due to
their increased activity levels. In humans, nausea is often
observed with Ex-4 treatment; however, in our paradigm it
is unlikely that this was in effect because this would likely
have negatively affected the animals’ rotarod performance.
Ex-4–treated Huntington’s disease mice showed supe-
rior motor control compared with the Huntington’s dis-
ease control animals, and treatment with Ex-4 recovered
Huntington’s disease rotarod performance times to a sim-
ilar proﬁciency as the wild-type control mice (Fig. 5A). As
Huntington’s disease symptoms progressed in the N171-
82Q mice, the control and Ex-4–treated Huntington’s
disease mice performed progressively worse on each
rotarod test. However, Ex-4 treatment signiﬁcantly
attenuated this decline in rotarod performance in the
Huntington’s disease mice, which indicates that Ex-4 can
ameliorate motor symptoms in Huntington’s disease mice
(Fig. 5B). Comparing the differences in performance (per-
cent change from baseline) from week to week of treat-
ment, we demonstrated that as a ratio of Ex-4 to control
animals, there was a consistent superiority of the Ex-4–
treated Huntington’s disease animals compared with sa-
line-treated Huntington’s disease animals. Hence, both
saline- and Ex-4–treated animals declined in performance
over time, but the Ex-4–treated animals each week had a
better performance than control animals., i.e., greater
positive change to baseline at week 4 and then lesser
decreases from baseline at weeks 6 and 8 (Fig. 5B and C).
mhtt aggregates are reduced with Ex-4 treatment.
Inclusions of aggregated huntingtin protein in cortical,
striatal, and hippocampal neurons are present in the
Huntington’s disease mice and in Huntington’s disease
patients. In the N171-82Q mice, intranuclear inclusions
and neuritic aggregates [all immunoreactive with an anti-
body to the NH2 terminus (amino acids 1–17) of hunting-
tin] have been shown to be present in multiple populations
of neurons (24). We determined whether Ex-4 treatment
had any efﬁcacy at reducing the number of mhtt aggregates
in both the brain (cortex) and pancreas (islets of Langer-
hans). Ex-4 treatment caused a reduction in the amount of
mhtt aggregates in the cortex of the Huntington’s disease
mice (Fig. 6A; P  0.01). Additionally, there was a small,
but nonsigniﬁcant, increase in Hsp-70 levels in the cortex
of both the wild-type and Huntington’s disease Ex-4–
treated mice compared with vehicle-treated mice. In the
pancreas, Ex-4 treatment caused a signiﬁcant reduction
(Fig. 6B; P  0.001) in the number of mhtt aggregates in
the islets of Langerhans. The Huntington’s disease control
mice showed a large number of mhtt aggregates in the
pancreatic islets. Typically, the Huntington’s disease con-
trol mice had two types of islets; very small islets contain-
ing a large number of mhtt aggregates and somewhat
larger irregular-shaped islets containing a large number of
mhtt aggregates. The Ex-4–treated Huntington’s disease
mice on the other hand demonstrated that only the smaller
islets contained a low number of aggregates and that
larger islets had few or no aggregates.
Ex-4 treatment extends the survival of Huntington’s
disease mice. Any effective therapeutic agent for the
treatment of Huntington’s disease symptomology would
ideally delay the onset of symptoms (i.e., motor dysfunc-
tion) and extend life span. In addition to ameliorating
motor dysfunction (Fig. 5), Ex-4 treatment resulted in a
highly signiﬁcant increase in the survival of the Hunting-
ton’s disease mice compared with vehicle-treated control
Huntington’s disease mice (Fig. 6C). The onset of mortality
in Huntington’s disease mice treated with Ex-4 was signif-
icantly delayed compared with the control Huntington’s
disease mice, and the mean life span was signiﬁcantly
increased from 140 to 165 days (P  0.01; Fig. 6C). This life
span–extending effect of Ex-4 of nearly 1 month repre-
sents an 18% increase over the life span of vehicle-treated
control Huntington’s disease mice.
DISCUSSION
We have shown that Ex-4, a potent long-acting agonist of
GLP-1 used to treat type 2 diabetes, signiﬁcantly improved
glycemic control and pancreatic cellular architecture, at-
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gregation in the brain and pancreas, and signiﬁcantly
increased life span in the N171-82Q mouse model of
Huntington’s disease. This is the ﬁrst study to report that
euglycemia can be achieved and maintained and that
pancreatic islets can be preserved in a mouse model of
Huntington’s disease by daily administration of a widely
used drug. The beneﬁcial effects of Ex-4 on abnormalities
of energy metabolism (glycemic control) and brain pathol-
ogy (mhtt-associated degeneration and motor dysfunc-
tion) are likely due to a combination of peripheral and
central actions of Ex-4. The global effects of Ex-4 are
clearly beneﬁcial to the animal even with the presence of
reduced body mass; thus, the treatment is still effective
even with this unwanted side effect. In human patients,
cognizance of this action may be offset by an increase in
input calories in their diet, which may be actually facili-
tated by Ex-4 treatment, because in the animals, it reduced
leptin levels and increased ghrelin levels. A simultaneous
reduction in satiety (lower leptin) and increase in hunger
(increased ghrelin) would help foster elevated caloric
intake in the Huntington’s disease patients.
The high basal glucose levels in Huntington’s disease
mice may be associated with accumulation of mhtt and,
therefore, disruption of function in pancreatic -cells,
reductions in numbers of -cells, and perturbed -cell
A
C
Control
Exendin-4
Control
Exendin-4
E
G
F
H
Insulin
Glucagon
B
D
A
FIG. 4. Treatment with Ex-4 improves pancreatic islet physiology in Huntington’s disease mice (right panel). Immunostaining of pancreatic tissue
for the -cell–derived hormone insulin and corresponding phase contrast images. A and B: Saline-treated Huntington’s disease mice had small,
signiﬁcantly diminished islets compared with saline-treated wild-type mice (left panel). C and D: Treatment with Ex-4 restored islet size in
Huntington’s disease mice but did not signiﬁcantly affect islet size in wild-type mice. Immunostaining for the -cell–derived hormone glucagon
conﬁrmed these improvements in islet physiology with Ex-4 treatment. E and G: In nondiabetic mice, glucagon-positive cells are typically
arranged in a “halo” around the edge of the islet. F: In the Huntington’s disease mice, the islet structure was altered, and -cells were displaced
into the center of the islet. H: This -cell abnormality was improved with Ex-4 treatment in Huntington’s disease mice. Values are means  SE,
n  6–8 animals per group. (Please see http://dx.doi.org/10.2337/db08-0799 for a high-quality digital representation of this ﬁgure.)
TABLE 1
Pancreatic islet size analysis of wild-type and N171-82Q Huntington’s disease mice treated with either saline or Ex-4
Wild type N171-82Q Huntington’s disease
Control Ex-4 P value Control Ex-4 P value
Islet area (m
2) 15,101  2,546 12,606  2,652 0.501 2,590  601 13,193  2,496 0.001*
Major axis (m) 211.5  19.0 185.3  21.5 0.369 91.6  11.6 203.9  31.9 0.003†
Minor axis (m) 154.1  13.5 132.7  13.6 0.272 65.8  8.6 126.1  13.1 0.001*
Data are means  SEM unless otherwise indicated. *P  0.001; †P  0.01.
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aggregates in pancreatic cells associated with perturbed
structure and endocrine function of the pancreas in Hun-
tington’s disease mouse models (11). We found that Ex-4,
based on the morphological ﬁndings, obviously amelio-
rates mhtt-related -cell pathologies, suggesting that the
beneﬁcial effects of Ex-4 on the pancreas are, at least in
part, responsible for its ability to restore glycemic control
in the Huntington’s disease mice. Of Huntington’s disease
patients, 20% are reported to have diabetes (10,36). This
incidence may prove to be higher if all Huntington’s
disease patients were tested. Insulin treatment (up to 8
IU/kg daily or twice daily) of long-acting insulin, a dose
that typically induces lethal hypoglycemia in normal mice,
did not control blood glucose in the Huntington’s disease
mice, illustrating a severe insulin resistance, and actually
appeared to shorten the life span of the Huntington’s disease
mice.
Ex-4 had profound effects on insulin resistance, as
demonstrated by the marked improvement in the HOMA
index. Plasma glucose levels of the Ex-4–treated Hunting-
ton’s disease mice were signiﬁcantly lower than those of
the nontreated Huntington’s disease animals, for the same
prevailing plasma insulin levels, clearly indicating im-
proved insulin action. We propose that this is due to direct
effects of Ex-4 on the brain as a result of reducing mutant
htt aggregates, and we suggest that the therapeutic locus
of improvement may be at the level of the hypothalamus.
Evidence indicates that while insulin is not a major
regulator of glucose use by the brain (37), the brain is
clearly not insulin insensitive. In normal rats, blockade of
insulin receptor signaling in the hypothalamus by phos-
phoinositide 3-kinase (PI 3-kinase) inhibitors leads to
hepatic insulin resistance and its inevitable consequence
of increased hepatic glucose production (38,39). Centrally
acting insulin may regulate glucose metabolism via neuro-
nal systems that are partially independent of one another
(39). Defective insulin receptor substrate/PI 3-kinase sig-
naling is implicated in insulin resistance in peripheral
tissues (40) and presumably may be causing neuronal/
hypothalamic insulin resistance in Huntington’s disease
patients. In addition to insulin control of PI 3-kinase
activity in the hypothalamus, the satiety-controlling hor-
mone leptin also activates PI 3-kinase in the hypothalamus
(41). Therefore, defective insulin/PI 3-kinase signaling in
hypothalamus would be compounded by the presence of
low leptin levels, as we found to be the case in the
Huntington’s disease mice. Intriguing data also point to
centrally acting carnitine palmitoyl transferase-1 (CPT-1),
the mitochondrial protein that regulates the rate of fatty
acid oxidation, being a regulator of peripheral insulin
sensitivity. Its inhibition centrally led to increased hepatic
insulin sensitivity that was functionally blocked by vagot-
omy (42). Lipid sensing by the brain appears to regulate
hepatic glucose metabolism via activation of vagal afferent
ﬁbers. We therefore suggest that in Huntington’s disease,
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FIG. 5. Ex-4 treatment improves motor coordination in Huntington’s disease mice. Motor performance was measured bi-weekly using an
accelerating rotarod apparatus. Mice were placed on the rotarod, which accelerated from 4 to 40 rpm over a 5-min test period, and latency to fall
was recorded. A: Average time spent on the rotarod during the course of treatment for each study group is shown. Treatment with Ex-4
signiﬁcantly increased the rotarod times of Huntington’s disease mice (P < 0.05). Ex-4 treatment also increased the rotarod latencies of wild-type
mice (P < 0.01). B: Analysis of percent change in rotarod performance from baseline conﬁrmed that the performance of the Ex-4–treated
Huntington’s disease mice showed a much slower rate of motor control decline than the saline-treated Huntington’s disease mice. Hence, at each
time trial, Ex-4–treated animals showed a greater time on the rotarod compared with saline-treated animals. C: The relative week-to-week
differences (modulus) in rotarod performance (percent change from baseline) between Ex-4– and control-treated Huntington’s disease animals
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lin resistance in the hypothalamus. This may also lead to
upregulation of CPT-1 and increased fatty acid oxidation,
further decreasing signaling via the vagus to the liver. The
defects related to glucose metabolism in the Huntington’s
disease mice were not corrected by exogenous insulin
(and presumably also could not be corrected by endoge-
nous insulin action), suggesting that mutant htt aggregates
are directly impacting the insulin receptor downstream
signaling pathways. Because Ex-4 lessened aggregates in
both the brain and the pancreas in our Huntington’s
disease mice, we hypothesize that this is the primary
mechanism underlying the ability to markedly improve
insulin action. Taken together, such a mechanism further
reinforces the potential impact of considering hormonal
periphery-central interactions with respect to therapeutics
for neurodegenerative disorders.
Neither the normal function of huntingtin nor the mech-
anism whereby the polyglutamine expansions result in
selective loss of striatal neurons is fully understood,
although impaired energy metabolism (43), excitotoxicity
(44), and oxidative stress (45) have all been implicated.
Mutant htt may cause neuronal dysfunction and death by
inducing oxidative stress, impairing energy metabolism,
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apoptosis (46). Deﬁcits in striatal and cortical glucose
metabolism have been shown to precede the appearance
of symptoms in Huntington’s disease patients (47), and
mhtt impairs neuronal energy metabolism in cultured
neurons and transgenic mice (48,49). The ability of Ex-4 to
suppress mhtt accumulation in brain cells and improve
motor performance in Huntington’s disease mice indicates
that Ex-4 counteracts the adverse effects of mhtt on
neurons at a relatively early stage in the neurodegenera-
tive process. Previous studies have shown that Ex-4
crosses the blood-brain barrier (21) and that small frag-
ments of Ex-4 have been shown in one study to mediate
neuronal protection against excitotoxic and metabolic
insults in culture and in vivo (22). Our ﬁndings suggest that
Ex-4 can protect neurons against the pathogenic actions of
mhtt, thereby delaying disease onset and extending the
survival of the Huntington’s disease mice.
Our understanding of neurodegenerative brain disorders
has evolved to a point at which brain health and somatic
health are intimately associated in the disease process.
The contribution of peripheral and glycemic health is
critical to the maintenance of a healthy brain (14). In
searching for an effective therapeutic strategy for Hunting-
ton’s disease, previous research has focused only on the
detrimental effects of aberrant mhtt processing in brain
cells, while largely overlooking the fact that peripheral
pathophysiology (such as altered glucose control, dis-
rupted energy expenditure, and severe uncontrolled
weight loss) could contribute to Huntington’s disease
symptomology and exacerbate neuronal dysfunction and
disease progression. Our ﬁndings show that Ex-4, an agent
that targets both the central (i.e., neuronal dysfunction)
and peripheral (abnormal energy and glucose regulation,
appetite dysregulation) pathological processes in Hunting-
ton’s disease, is a therapeutic agent in Huntington’s dis-
ease mice. When taken together with the increasing
evidence that GLP-1 and Ex-4 can protect neurons against
a range of insults (22) and can stimulate neurogenesis
(50), our ﬁndings suggest that Ex-4 might also prove
efﬁcacious in other complex neurodegenerative disorders
that involve metabolic disturbances, including Alzheimer’s
and Parkinson’s diseases. Regardless of all else, our data
suggest that Ex-4, now marketed as exenatide, should be
seriously considered for treating metabolic deﬁcits in
Huntington’s disease patients.
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